Cargando…

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

BACKGROUND: Results from the recent CROSS trial showed that neoadjuvant chemoradiotherapy (nCRT) significantly increased survival as compared to surgery alone in patients with potentially curable esophageal cancer. Furthermore, in the nCRT arm 49% of patients with a squamous cell carcinoma (SCC) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noordman, Bo Jan, Shapiro, Joel, Spaander, Manon CW, Krishnadath, Kausilia K, van Laarhoven, Hanneke WM, van Berge Henegouwen, Mark I, Nieuwenhuijzen, Grard AP, van Hillegersberg, Richard, Sosef, Meindert N, Steyerberg, Ewout W, Wijnhoven, Bas PL, van Lanschot, J Jan B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications Inc. 2015
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526968/ https://www.ncbi.nlm.nih.gov/pubmed/26121676 http://dx.doi.org/10.2196/resprot.4320

Ejemplares similares

Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial
por: van der Wilk, B. J., et al.
Publicado: (2020)

Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer
por: Eyck, Ben M., et al.
Publicado: (2021)

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial
por: Noordman, Bo Jan, et al.
Publicado: (2018)

Study protocol for the nutritional route in oesophageal resection trial: a single-arm feasibility trial (NUTRIENT trial)
por: Weijs, Teus J, et al.
Publicado: (2014)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

Early onset esophageal adenocarcinoma: a distinct molecular entity?
por: van Nistelrooij, Anna M.J., et al.
Publicado: (2016)

Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Review of Meta-Analyses
por: Wijnhoven, Bas P. L., et al.
Publicado: (2009)

Effects of exercise after oesophagectomy on body composition and adequacy of energy and protein intake: PERFECT multicentre randomized controlled trial
por: Hiensch, Anouk, et al.
Publicado: (2023)

Patients’ Preferences for Surgical Management of Esophageal Cancer: A Discrete Choice Experiment
por: de Bekker-Grob, Esther W., et al.
Publicado: (2015)

Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer
por: Talsma, Koen, et al.
Publicado: (2012)

Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial)
por: Haverkamp, Leonie, et al.
Publicado: (2015)

Digital Self-Management Support Tools in the Care Plan of Patients With Cancer: Review of Randomized Controlled Trials
por: Adriaans, Danielle JM, et al.
Publicado: (2021)

Delay in Diagnostic Workup and Treatment of Esophageal Cancer
por: Grotenhuis, Brechtje A., et al.
Publicado: (2009)

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas
por: Creemers, Aafke, et al.
Publicado: (2018)

Four cancer cases after esophageal atresia repair: Time to start screening the upper gastrointestinal tract
por: Vergouwe, Floor WT, et al.
Publicado: (2018)

Expectations of Continuous Vital Signs Monitoring for Recognizing Complications After Esophagectomy: Interview Study Among Nurses and Surgeons
por: van Rossum, Mathilde, et al.
Publicado: (2021)

Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract
por: Damhofer, Helene, et al.
Publicado: (2015)

Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
por: Hermus, Merel, et al.
Publicado: (2022)

Perceived facilitators and barriers by esophageal cancer survivors participating in a post-treatment exercise program
por: van Vulpen, Jonna K., et al.
Publicado: (2023)

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
por: Steins, Anne, et al.
Publicado: (2017)

Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial
por: Boonstra, Jurjen J, et al.
Publicado: (2011)

Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study
por: Markar, S. R., et al.
Publicado: (2017)

Characteristics Predicting Short-Term and Long-Term Health-Related Quality of Life in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy and Esophagectomy
por: van der Wilk, Berend J., et al.
Publicado: (2023)

Piernas ligeras para un cuerpo sano
por: Lepage, Jan

Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)
por: van Heijl, M, et al.
Publicado: (2008)

The dynamics of HER2 status in esophageal adenocarcinoma
por: Creemers, Aafke, et al.
Publicado: (2018)

Patient-Related Prognostic Factors for Anastomotic Leakage, Major Complications, and Short-Term Mortality Following Esophagectomy for Cancer: A Systematic Review and Meta-Analyses
por: van Kooten, Robert T., et al.
Publicado: (2021)

Using the Comprehensive Complication Index to Assess the Impact of Neoadjuvant Chemoradiotherapy on Complication Severity After Esophagectomy for Cancer
por: Nederlof, Nina, et al.
Publicado: (2016)

Incidence, Stage, Treatment, and Survival of Noncardia Gastric Cancer
por: van Velzen, Merel J. M., et al.
Publicado: (2023)

Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer
por: Eyck, Ben M, et al.
Publicado: (2022)

El niño Sano
Publicado: (2001)

El niño sano /
Publicado: (2005)

Distal Versus Total D2-Gastrectomy for Gastric Cancer: a Secondary Analysis of Surgical and Oncological Outcomes Including Quality of Life in the Multicenter Randomized LOGICA-Trial
por: de Jongh, Cas, et al.
Publicado: (2023)

Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples
por: van Nistelrooij, Anna M. J., et al.
Publicado: (2017)

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma
por: Ebbing, Eva A., et al.
Publicado: (2019)

Body Composition Is a Predictor for Postoperative Complications After Gastrectomy for Gastric Cancer: a Prospective Side Study of the LOGICA Trial
por: Tweed, Thaís T. T., et al.
Publicado: (2022)

Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma
por: van Nistelrooij, Anna M. J., et al.
Publicado: (2015)

Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS)
por: Toxopeus, Eelke, et al.
Publicado: (2018)

The Value of Paratracheal Lymphadenectomy in Esophagectomy for Adenocarcinoma of the Esophagus or Gastroesophageal Junction: A Systematic Review of the Literature
por: Gantxegi, Amaia, et al.
Publicado: (2021)

NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial)
por: van Heijl, Mark, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_bqn1nh5n2kij552ot36ljpti6h